Devyser’s Deputy CEO and founder Ulf Klangby moves to an advisory role
Devyser’s Deputy CEO and founder Ulf Klangby will leave his position within the company for an advisory role as a consultant as of July 1, 2023.
Ulf Klangby will leave his operational role as part of the group management team and instead support the company as a consultant. In his consulting role, Ulf will support the company in areas including business development, patent-related issues and the evaluation of future products and technologies.
“Devyser has been on an incredible journey since we founded the company 19 years ago. It has now entered a very exciting phase, with an attractive product portfolio and stronger presence in key markets. I am now looking forward to continuing to contribute to and support the company as an advisor and a committed owner”, commented Ulf Klangby, Deputy CEO of Devyser.
Ulf Klangby founded Devyser in 2004 together with Anders Hedrum and Dan Hauzenberger, and was the company’s CEO from 2004 to 2020 and a member of the company’s Board of Directors from 2004 to 2021.
As of July 1, the company’s group management team will comprise Fredrik Alpsten, CEO, Sabina Berlin, CFO, Theis Kipling, CCO, Göran Rydin, COO, and Camilla Wiberg, CHRO.
This information was submitted for publication by the contact person below on June 5, 2023 at 08:00 CET.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for complex genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser’s products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in Stockholm, Sweden. The company has eight in-house sales offices in Europe and the US, and a CLIA laboratory in Atlanta, Georgia. In August 2022, Devyser’s quality management system and Devyser Compact were IVDR certified.
Devyser’s shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB.
For more information, visit www.devyser.com.